Sort
82,697 grants matching “vaccine development”
Advanced Development of Vaccines for Antibiotic Resistant Bacteria
$1,649,387Frank Malinowski · Eveliqure Biotechnologies, Gmbh · N01 · FY2022 · AI
The Atlantic Coast Sexually Transmitted Infection Cooperative Research Center (AC
$1,648,842Ann E. Jerse · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2015 · AI
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
$1,648,211David Burkhart · Inimmune Corporation · N01 · FY2025 · AI
SALMONELLA CAUSE AN ESTIMATED 1.4 MILLION CASES OF FOODBORNE DISEASE, RESULTING IN ~13,000 HOSPITALIZATIONS, AND >500 DEATHS ANNUALLY IN THE UNITED STATES. THERE ARE CURRENTLY NO TREATMENTS FOR UNCOMPLICATED SALMONELLA INFECTIONS, OR INTERVENTIONS TO BLOCK PERSISTENT FECAL SHEDDING OF THIS ORGANISM FROM LIVESTOCK. THE GOAL OF THIS PROPOSAL IS TO UNDERSTAND HOW SALMONELLA, A COMMON AGENT OF BACTERIAL FOODBORNE DISEASE IN HUMANS, CAN SURVIVE AND GROW IN THE INTESTINE DURING INFECTION. OUR HYPOTHESIS IS THAT SALMONELLA ENCODES PROTEINS THAT ALLOW IT TO GROW IN THE INTESTINE IN OXYGEN-LIMITED CONDITIONS, AND WE DO NOT YET KNOW THE FUNCTIONS OF MANY OF THESE PROTEINS. WE HAVE DISCOVERED 16 GENES THAT APPEAR TO BE IMPORTANT FOR SALMONELLA GROWTH IN THE INTESTINE AND THE GOAL OF THIS PROJECT IS TO IDENTIFY THE FUNCTIONS OF SEVERAL OF THE PRODUCTS OF THESE GENES. THE OBJECTIVES OF THIS PROJECT ARE TO (1) MEASURE THE SURVIVAL AND GROWTH OF STRAINS LACKING THESE GENES BOTH IN THE INTESTINE AND IN OXYGEN LIMITED CONDITIONS IN THE LABORATORY, (2) TO IDENTIFY WHICH OF THESE GENES PARTICIPATE IN VIRULENCE PATHWAYS THAT ARE ALREADY KNOWN, (3) TO IDENTIFY THE FUNCTIONS OF PRODUCTS OF SELECTED GENES, AND (4) TO MODEL THE STRUCTURE AND POTENTIAL SUBSTRATES OF SELECTED CANDIDATE GENE PRODUCTS. THIS KNOWLEDGE CAN BE USED IN THE FUTURE TO DEVELOP NEW VACCINES AND DRUGS TO PREVENT AND TREAT SALMONELLA INFECTIONS IN HUMANS AND LIVESTOCK.
$1,647,845Texas A & M University System Health Science Center · · FY2017 · National Institute of Food and Agriculture
Immune Response Consortium: Integrated In Silico, In Vitro, and In Vivo Studies
$1,647,491Arup K. Chakraborty · Massachusetts Institute Of Technology · P01 · FY2010 · AI
DNA Sequencing and FACS Core Facilities
$1,646,795Paul Robbins · Division Of Basic Sciences - Nci · ZIC · FY2013 · CA
The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys
$1,646,529Sallie R. Permar · Duke University · P01 · FY2019 · AI
Exploring the impact of inflammaging on immune function during M. tb infection
$1,646,449Joanne Turner · Ohio State University · P01 · FY2016 · AG
Understanding and Altering the Virologic Setpoint
$1,645,592Aaron Diamond Aids Research Center · U01 · FY2004 · AI
MECHANISMS PROGRAMMING PROTECTIVE IMMUNITY FROM RhCMV-SIV VACCINE AND IL-15 ACTIONS
$1,645,537Michael J Gale · University Of Washington · P01 · FY2023 · AI
Administrative Core
$1,645,297Shan Lu · Univ Of Massachusetts Med Sch Worcester · U19 · FY2011 · AI
Institutional Career Development Core
$1,644,899Emma Anne Meagher · University Of Pennsylvania · KL2 · FY2024 · TR
Mechanisms of naturally-acquired immunity to malaria
$1,644,331Peter Crompton · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Task X8: Efficacy Testing of Ebola Virus Vaccines
$1,644,104Carol Sabourin · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2014 · AI
National AIDS Research Institute (NARI), Pune, INDIA: Clinical Trials Unit
$1,642,668Sheela Virendra Godbole · National Aids Research Institute · UM1 · FY2013 · AI
CCR Genomics Core
$1,642,585Elizabeth Conner · Division Of Basic Sciences - Nci · ZIC · FY2020 · CA
Innate Immune Antivirals for Biodefense
$1,642,398Michael J Gale · University Of Washington · R01 · FY2014 · AI
Novel Approaches to Stem Cell Transplantation
$1,642,204Duke University · P01 · FY2005 · CA
San Antonio STI TM CRC
$1,641,907University Of Texas Hlth Sci Ctr San Ant · U19 · FY2005 · AI
Development Of A Vaccine For Leishmania Major Infection
$1,641,899Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Optimization Of HIV Specific Immune Responses In Vivo
$1,641,899Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Philadelphia IMPAACT Clinical Trials Unit
$1,641,630Steven Daniel Douglas · Children'S Hosp Of Philadelphia · U01 · FY2007 · AI
DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM
$1,641,451Jay Evans · University Of Montana · N01 · FY2025 · AI
UCLA AIDS Prevention and Treatment Clinical Trials Unit
$1,641,447Judith S. Currier · University Of California Los Angeles · UM1 · FY2017 · AI
Vaccine Production Core
$1,641,287Thomas N Denny · Duke University · U19 · FY2009 · AI